GlassScriptPhysician profile
Laneasha Marie Eudell
NPI 1811407745
$15,222.19
in general payments reported to CMS, 2019-2025
23 companies · $1,878 in 2025
The $1,878 reported for 2025 was more than what 91% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $4,594 · 2022: $1,988 · 2023: $4,100 · 2024: $2,661 · 2025: $1,878.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,359 · Education: $281.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,358.58 |
| Education | $280.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $3,397.71 | 2021-2025 | Caplyta |
| Alkermes, INC. | $1,605.59 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Abbvie INC. | $1,422.46 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $1,285.91 | 2021-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Janssen Pharmaceuticals, INC | $1,174.04 | 2021-2024 | Spravato, Invega Sustenna, Invega Trinza |
| Lundbeck LLC | $955.99 | 2021-2025 | Rexulti |
| Sunovion Pharmaceuticals INC. | $868.34 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $776.84 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Takeda Pharmaceuticals U.S.A., INC. | $756.40 | 2021-2024 | Trintellix |
| Axsome Therapeutics, INC. | $620.41 | 2022-2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $588.32 | 2021-2023 | Fanapt, Hetlioz |
| Indivior INC. | $413.20 | 2021-2024 | Perseris |
| Neurocrine Biosciences, INC. | $405.56 | 2021-2025 | Ingrezza |
| Bausch Health US, LLC | $326.35 | 2021 | |
| Supernus Pharmaceuticals, INC. | $158.24 | 2022-2023 | Qelbree |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $152.35 | 2023-2024 | Epclusa |
| E.R. Squibb & Sons, L.L.C. | $125.00 | 2024 | Cobenfy |
| Eisai INC. | $45.29 | 2021 | |
| Jazz Pharmaceuticals INC. | $41.78 | 2021 | |
| Braeburn INC. | $40.59 | 2023-2024 | Brixadi |
| Almatica Pharma LLC | $21.54 | 2021 | |
| Tris Pharma INC | $21.09 | 2021 | |
| Ironshore Pharmaceuticals INC. | $19.19 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laneasha Eudell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.